Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2025-04-27 Environmental & Social …
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
环境、社会和公司治理（ESG）管理制度
Environmental & Social Information Classification · 95% confidence The document is titled '环境、社会和公司治理（ESG）管理制度' which translates to 'Environmental, Social and Corporate Governance (ESG) Management System'. It details the company's ESG management policies, responsibilities, governance structure, stakeholder rights, environmental protection, social responsibility, and ESG reporting and disclosure practices. The content is a comprehensive policy document outlining the company's ESG framework rather than a report of ESG performance or data. It does not contain financial statements or earnings data, nor is it an announcement or certification. The document fits the category of Environmental & Social Information (ESG) as it focuses on the company's ESG management system and related governance practices.
2025-04-27 Chinese
关于控股子公司再次通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (661 characters) about a controlling subsidiary of the company receiving a renewed High-Tech Enterprise Certificate, which allows preferential tax treatment. It does not contain financial statements, detailed financial data, or management discussion. It is an official announcement regarding a regulatory or tax status update, not a full report or detailed financial disclosure. The document is not a report itself but an announcement of a certification or status update. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-04-22 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the approval of a pharmaceutical product, its specifications, and the impact on the company. The document is short (1323 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release of a report but rather announces a regulatory milestone. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-04-08 Chinese
关于收到药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about receiving an approval notice from a regulatory authority (国家药品监督管理局) regarding a supplementary drug application. It details the drug name, changes approved, and the impact on the company. The document is short (956 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-21 Chinese
关于变更持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of continuous supervision sponsor representatives for a company's non-public stock issuance project. It details personnel changes and includes a biography of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or meeting materials. This fits the category of a regulatory announcement about management or supervisory changes related to financing activities but not the financing update itself. It is not a full management change announcement (MANG) since it concerns sponsor representatives, not company board or senior management. The best fit is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-03-10 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving a drug registration certificate from the national drug regulatory authority. It details the drug name, registration number, approval date, and expected impact on the company. There is no financial data, no mention of financial results, no management discussion, no voting results, no share transactions, no legal proceedings, no merger or acquisition activity, and no report publication. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-03-10 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.